New research finds salivary antioxidants and oxidative stress could be important biomarkers for plaque psoriasis.
Total oxidative stress and oxidative stress index values in the saliva may be useful as a diagnostic biomarker for plaque psoriasis, according to new research.
A team of scientists from the Medical University of Bialystok, in Poland, wanted to generate useful biomarkers to diagnose plaque psoriasis by examining the redox balance parameters and oxidative stress in the saliva and blood of patients.
To do so, the investigators recruited 40 healthy adult patients and 40 patients with plaque psoriasis. They decided to look at salivary parameters in addition to blood, in part because saliva is easier to collect, causes lower anxiety in patients and has the potential to make it easier for patients to monitor their own health.
Salivary redox balance has been found to be a useful biomarker in a number of diseases, but until this study no one had tried evaluating it as a tool for diagnosing psoriasis patients.
After testing the 80 patients in the study, a number of statistically significant differences were clear.
“We... demonstrated that plaque psoriasis disturbs enzymatic antioxidant systems in saliva and leads to oxidative damage to salivary proteins and lipids,” writes Anna Skutnik-Radziszewska, a doctoral student at the university, and the study’s corresponding author. “We observed that intensification of oxidative modifications of proteins and lipids in saliva correlated with the disease duration.”
The results were published last month in Oxidative Medicine and Cellular Longevity. Specifically, Skutnik-Radziszewska and colleagues found:
Taken together, the investigators found that saliva can be a highly meaningful diagnostic avenue in psoriasis.
“The fact is not surprising as the concentration of numerous substances in saliva correlates with their content in the blood serum, and saliva is a noninvasive, noninfectious, and relatively stable laboratory material,” they write.
However, they argue that total oxidative stress (TOS) and oxidative stress index (OSI) value are particularly notable metrics.
“The diagnostic value of TOS and OSI is also emphasized by the positive correlation between the disease duration as well as [psoriasis area and severity index] and the content of TOS and OSI in [unstimulated saliva] and plasma,” they write.
TOS and OSI are therefore potentially strong biomarkers for psoriasis, they conclude.
Reference
Skutnik-Radziszewska A, Maciejczyk M, Fejfer K, et al. Salivary antioxidants and oxidative stress in psoriatic patients: Can salivary total oxidant status and oxidative status index be a plaque psoriasis biomarker [published online January 3, 2020]. Oxid Med Cell Longev. doi:10.1155/2020/9086024.
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinarof cream.
Read More
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
August 3rd 2021August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.
Listen
Study Finds Link Between Depression, Functional Impairment in Psoriasis, Psoriatic Arthritis
November 24th 2023Depression symptoms are often underdiagnosed and undertreated in patients with psoriasis and psoriatic arthritis, contributing to a worsened quality of life (QOL). However, a recent study found that depression, functional impairment, and worsened QOL are related.
Read More
Evaluating Work Productivity, Efficacy and Safety of Tildrakizumab in Patients With Plaque Psoriasis
November 13th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.
Read More
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More